

# **RESEARCH ARTICLE**

# PREVALENCE OF RISK FACTORS FOR OSTEOPOROSIS AMONG FEMALES AGED 35 YEARS AND ABOVE IN SAUDI ARABIA

Manal Abdulaziz Murad, Fatimah Fahad Altaleb, Hussam Mahmoud Baeissa, Saleh Sameer Ashgar, Ghaliah Amin Thiga, Rahaf Abdulaziz Alharbi, Rakan Fuad Ashour, Raghad Abdulaziz Alharbi, Fatimah Hassan Alzubaidi, Jameelah Mohammed Alzaheri, Rafal Taleb Fareedi, Muhanna Farhan Al Osaimi, Seham Salem Almohammadi, Sama Ahmad Alostaz

- 1. Assistant Professor and Consultant Family Medicine, Department of Family Medicine, Faculty of Medicine, King Abdulaziz University, KSA.
- 2. R3 internal medicine, Security forces hospital, Riyadh, KSA.
- 3. GP ICU Resident, King Abdullah Medical Complex Jeddah, KSA.
- 4. Physician, Maternity and Children Hospital, Makkah, KSA.
- 5. Medical Intern, KSA.
- 6. Medical Student, KSA.

# Manuscript Info

# Abstract

*Manuscript History* Received: 31 October 2020 Final Accepted: 30 November 2020 Published: December 2020

*Key words:-*Osteoporosis, Prevalence, Risk Factors, Vitamin D Deficiency Osteoporosis is a common public health challenge globally but the relative contribution of variousrisk factors for osteoporosis in Saudi Arabia is not well established. We conducted this study to determine the prevalence of risk factors for osteoporosis among females aged 35 years and above in Saudi Arabia. We performed a descriptive cross-sectional study with a sample size of 2070 and determined the prevalence of risk factors as percentages of the total sample size. We foundthat vitamin D deficiency is the major modifiable risk factor for osteoporosis in Saudi Arabia followed by cigarette smoking. Autoimmune and endocrine diseases were also not uncommon. Our results therefore suggest for the strengthening of measures to prevent vitamin D deficiency, reduce corticosteroid-related osteoporosis and curb cigarette smoking.

Copy Right, IJAR, 2020,. All rights reserved.

# **Introduction:-**

(

Osteoporosis is a disorder manifested by unusually low bone mass and a deformity in the microstructure of the bone making itweak and at a greater propensity to fracture than normal<sup>[1]</sup>. Osteoporosis is not uncommon in Saudi Arabia. In one study, 34% of women, and 30.7% of men between 50 to 79 years of agehad osteoporosis<sup>[2]</sup>. Bone loss in osteoporosis is caused by osteoclastic bone resorption, reduced bone deposition or the two acting together. The causefor fragility of the bone is not only the reduction in bone mass but also thedefect in the microstructure of the remaining trabecular bone. Skeletal fragility is therefore related to many other factors including the rate of bone

.....

1	Corresponding Author:- Dr. Hoda Jehad Abousada
ļ	Address:- M.D KFAFH: King Fahd Armed Forces Hospital.

commonly to hass in the third icle stimulating

hormone are also associated with hypogonadal osteoporosis of menopause . In these women, there is a well-

knownearly rapid bone loss due primarily to heightened osteoclastic bone resorption after the release of oestrogen restrain. There is also a gradual loss of osteoblastic bone deposition that is contributed by nutritional deficiencies, chronic illnesses, and impaired ambulation of old age. After menopause, bone depletion usually accelerates to about 3% per year which is ten times faster than the previous two decades. Genetic predisposition contributes greatly in postmenopausal osteoporosis but also other risk factors including Caucasian ethnicity, low body mass index, history of amenorrhoea, early onset of menopause, oophorectomy, early hysterectomy, physical inactivity, cigarette smoking, alcohol abuse, inadequate calcium consumption, vitamin D deficiency, and the number of pregnancies have been identified <sup>[5,6]</sup>. In pre-menopausal women, low bone mass can be attributed to secondary causes. Oestrogen deficiency from any cause such as hypogonadotropic hypogonadism resulting from low body mass index, psychiatric disorders such as anorexia nervosa, hyperprolactinemia, and hypopituitarism or hypergonadotropic hypogonadism due to various aetiologies including chromosomal abnormalities such as Turner syndrome and fragile X syndrome, toxins such as chemotherapy and radiation, and autoimmune diseases are but few<sup>[7]</sup>. Drugs such as glucocorticoids, anticonvulsants, antidepressants and depot medroxyprogesterone acetate are linked to osteoporosis of premenopausal<sup>[7]</sup>. Bone depletion is common in overt hyperthyroidism that carries an increased risk for fracture<sup>[8]</sup>. Subclinical hyperthyroidism is also causes low bone mass, particularly in the cortical bone with hightened risk of fracture <sup>[9]</sup>. Although the classic osteitis fibrosa cystica is rare today, the bone; particularly at more cortical sites, remains a target for primary hyperparathyroidism<sup>[10]</sup>. Hyperparathyroidism secondary to chronic kidney disease results to osteoporosis that affects predominantly the hip<sup>[11]</sup>. In inflammatory boweldisease (IBD), osteoporosis is found in 18 to 42 per cent of patients<sup>[12,13]</sup>. The aetiology of fragile bones in IBD usually emanate from multiple factors including corticosteroid therapy, disease-related systemic inflammation, malabsorption and hypogonadism<sup>[14,15]</sup>. Osteoporosis is commonest in patients with IBD who have been given little corticosteroid therapy and who have vitamin D deficiency<sup>[16]</sup>. Celiac disease also presents n increased risk to osteoporosis<sup>[17,18]</sup> and fractures<sup>[19]</sup> that can occur even in patients without gastrointestinal symptoms. Osteoporosis in celiac disease is due mainly to secondary hyperparathyroidism resulting from vitamin D deficiency<sup>[20]</sup>. Other autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematous also predisposes to osteoporosis. Although the extent of rheumatoid arthritis in Saudi Arabia is not well established, the problem is not uncommon<sup>[21]</sup>. Thyroid gland disease, which predisposes to osteoporosis, is not uncommon in the Arab region and is predominantly contributed by factors that are potentially modifiable<sup>[22]</sup>. Despite efforts to prevent cigarette smoking in public places, smoking remains a public health challenge in Saudi Arabia that heighten the risk forcancer and osteoporosis<sup>[23]</sup>. Cancer including gastrointestinal cancers and resultant gastrointestinal surgeries also causes osteoporosis and fractures <sup>[24]</sup>. Due to the paucity of data regarding the relative contribution of various risk factors for osteoporosis and the high prevalence of modifiable risk factors that predisposes directly or indirectly to osteoporosis, we conducted this study to determine the prevalence of risk factors for osteoporosis among females aged 35 years and above living in Saudi Arabia. Some studies<sup>[25,26]</sup> have established modifiable risk factors for osteoporosis such as vitamin D deficiency but did not particularly address the problem in the population of females aged 35 years and above which is at most high risk for osteoporosis. In this study, we also identified the prevalence of diseases that are associated directly or indirectly with osteoporosis in Saudi Arabia.

# **Materials And Methods:-**

# Study design

A descriptive cross-sectional study was done to determine the prevalence of risk factors for osteoporosis among females aged 35 years and above residing in the Kingdom of Saudi Arabia. All females aged 35 years and above were included in this study. Only participants who refused to consent for the study or with communication barrier were excluded.

# Sampling method

A non-probability convenient sampling technique was employed in this study.Participants were selected based on accessibility and proximity to theking Abdul-Aziz University and Hospital. A total of 2070 participants aged 35 years and above were enrolled. All participants were eligible and consented to participate in this study. All the collected data were complete with an overall response rate of 100%.

#### Data collection and analysis

Medical students from the king Abdul-Aziz University were trained and involved in data collection that took place from May 2019 to May 2020.Data were collected using a structured interview with a questionnaire. The questionnaire's first section consisted of socio-demographic characteristics including age, nationality and whether they were in-patients or found in out-patient settings at the instance of data collection. The second section of the questionnaire consisted of risk factors for osteoporosis. The questionnaire was developed in both English and Arabic forms and enough time was given during the interview together with adequate explanation of medical terms in layman's language to minimize recall bias. Data analysis was thereafter performed using IBM SPSS software version 17.0 (Chicago: SPSS Inc.)and prevalence of each risk factor expressed as the percentage of the total sample population.

# Ethical considerations

Administrative approval was sought from the unit of biomedical ethics research committee. Ethical approval was sought from the ethical committee of the faculty of medicine, king abdulaziz university, Saudi Arabia. Participants were informed about the purpose of the study and that participation wasfully voluntary. An informed consent was obtained from participants and participants had absolute autonomyto withdraw from the study at any moment during the course of the study. To ensureconfidentiality, the identity of the participants was closed.

# **Results:-**

## Socio-demographic characteristics

Most of our subjects were between 35 to 40 years old and Saudi in nationality. Of all, 71.4% were interviewed from outpatient settings (Table 01).

## Prevalence of risk factors for osteoporosis among the study participants

Vitamin D deficiency was the most common modifiable risk factor present in 60.4% of subjects followed by cigarette smoking present in 11.1% of subjects. Genetic factor was the second most prevalent risk factor for osteoporosis present in 28.2% of subjects and the most common among non-modifiable risk factors. Hormonal problems accounted for 19.3% of subjects while thyroid gland disease was present in 16% of subjects. Other endocrine causes were rare (Table 02). Autoimmune diseases were also rare with rheumatoid arthritis being the most common; present in 9.6% of subjects. Of all, 8.7% of subjects were on long-term systemic corticosteroids. Only 1.8% of subjects had cancer.

# **Discussion:-**

The chief function of vitamin D is, first: to enhance the absorption and transport of calcium from the gut, second:to facilitate bone remodelling by acting together with parathyroid hormone. Cholecalciferol, a natural form of vitamin D, is obtained primarily from the epidermis by the effect of ultraviolet radiation and secondarily from dietary sources. Insufficient exposure to sunlight, dietary deficiencies, or impairment in endogenous synthesisprocess, can lead todeficiency of vitamin D. The deficiency of vitamin D, although controversial, is defined as serum levels of less than 20ng/mL<sup>[27]</sup>. In most places, vitamin D is obtained from exposure to sunlight. The deficiency of vitamin D causes secondary hyperparathyroidism and depletion of bone; resulting to osteoporosis, and osteomalacia in the long term<sup>[28]</sup>. In our study, vitamin D deficiency was found in 60.4% of all participants. Our finding is consistent with studies that show the increasing prevalence of vitamin D deficiency worldwide<sup>[29,30]</sup>. This highlights the need to address vitamin D deficiency as a public health problem in Saudi Arabia especially to populations at risk. Osteoporosis is a common cause of morbidity in IBD causing fractures for several reasons including the diseaserelated systemic inflammation, corticosteroid therapy, hypogonadism, and vitamin D and calcium deficiency with advanced age and low BMI further increasing the risk<sup>[31]</sup>. In our study, 26.1% of participants had IBD. This further highlights the necessity of preventing vitamin D deficiency. Thyroid hormone stimulated both bone deposition and resorption, but more rapidly the latter by primarily stimulating osteoclasts or by stimulating osteoblasts which bring about bone resorption by osteoclats<sup>[32]</sup>. Hyperthyroidism is therefore linked to rapid bone resorption and osteoporosis. Both overt and subclinical hyperthyroidism present a considerable risk for fracture<sup>[8,33]</sup>. In our study, 16% of participants had a thyroid disease which put them at risk for osteoporosis. Although the reduction of bone mass in hyperparathyroidism is more on the cortical than trabecular bones<sup>[34]</sup>, and usually small, vertebral fractures are not uncommon in patient with primary hyperparathyroidism<sup>[35-36]</sup>. Celiac disease, although rare: present in only 1.7% of our subjects, causes hyperparathyroidism secondary to the deficiency of vitamin D leading to heightened propensity to fracture in patients with celiac disease<sup>[19,20]</sup>. Secondary hyperparathyroidism also occurs in chronic kidney disease that was found, together with chronic liver disease, in 8.7% of our subjects. Our findings were comparable to results from a community-based pilot study that found 5.7% prevalence of chronic kidney disease in the young Saudi population<sup>[37]</sup>. The long standing use of glucorticoids in rheumatoid arthritis (RA) can cause several complicationsincluding an increased risk of osteoporosis and skeletal fractures. In patients using prednisolone, the complications depends on the dose of prednisolone and mainly occur at doses greater than or equal to 5mg per day but even at doses lower than 2.5mg per day, complications can be evident <sup>[38-39]</sup>. Bone depletion in RA is greater

with less tolerance to weight bearing exercises and can be partially attenuated by increased mobility<sup>[40]</sup>. In our study, 9.6% of subjects had RA and therefore an increased propensity of osteoporosis and fractures. This finding underscores the benefits of treating all patients of RA on chronic therapy at doses of prednisolone above 5mg per day with 1000mg per day and 400 to 800 IU per day vitamin D supplementation<sup>[38]</sup>.Long-term use of systemic corticosteroids is among the major aetiologies of osteoporosis. One study revealed that only few patients on longterm systemic corticosteroids receive primary prevention therapies against iatrogenic osteoporosis induced by corticosteroids<sup>[41]</sup>. In our studywe found that 8.7% of subjects were in long-term use of systemic corticosteroids for various medical conditions. This finding too highlights the utility of using calcium and vitamin D as primary privative measure against corticosteroid-induced osteoporosis and related fractures. Evidence demonstrates that tobacco smoking causes deregulation of bone turnover through the RANKL-RANK-OPG pathway, causingaccelerated bone loss; making the bone susceptible to osteoporosis and fracture<sup>[42]</sup>. Although many strong risk factors for osteoporosis such as family history of osteoporosis: that was present in 28.2% of our subjects, and menopause, are not modifiable, cigarette smoking: present in 11.1% of our subjects, is a potentially modifiable target for public health intervention in Saudi Arabia where recent findings; despite public health efforts to curb smoking, suggest increased tobacco smoking<sup>[23,43]</sup>. Cancer is also one of the major risk factors for bone loss and fractures. This is due both to direct effects of malignant cells on the bone and to deleterious effects of chemotherapies on bone cells<sup>[44]</sup>.Despite the fact that the prevalence of cancer in Saudi Arabia is low compared to other countries, as well as the overall global population, it has risen significantly over the last two decades<sup>[45]</sup> calling for public health interventions to prevent obesity and improve diet and exercise<sup>[46,47]</sup>. Although the prevalence of SLE in Saudi Arabia is not accurately known, we found SLE in only 1% of our subjects. Some studies have found a higher incidence of SLE among Arab-Americans compared to non-Arab Caucasians and African Americans but little was known about the epidemiology of SLE among the Arab population worldwide or in the Middle East<sup>[48]</sup>. Nonetheless, SLE presents a high risk to osteoporotic fracture without prior symptoms<sup>[49]</sup>.

## **Study Limitations**

The major limitation of this study was the possibility of under-reporting or false reporting because this study was self-reporting in nature. Secondly, since this study was conducted at King Abdul-Aziz University and Hospital settings, the findings may not be representative of the whole population of Saudi Arabia. Finally, the information provided could not be verified.

# **Conclusion:-**

According to our study, the deficiency of vitamin D is the major modifiable risk factor for osteoporosis in Saudi Arabia followed by genetic predisposition as the most common non-modifiable risk factor. The prevalence of inflammatory bowel disease was higher than endocrine causes of osteoporosis with hormonal problems found in 19% of subjects. Thyroid disease was present in 16% of subjects. Cigarette smoking was the second commonestrisk factor that can be modified through public health interventions. Although autoimmune diseases were rare, rheumatoid arthritis was the most common. Taken together, our findings call for primary prevention of the deficiency of vitamin Dand corticosteroid-related bone depletion in people with autoimmune diseases and long-term corticosteroid use. We also highlight the need for lifestyle changes to prevent cancer-related osteoporosis and fractures.

# Acknowledgement:-

We thank the data collectors: Fatimah AiydAlqahtan, Ather Faisal Ageeli, Rahaf Mohammad Alqahtani, and Yara Jawad Alhamayl.

#### **Source Of Funding**

This study was self-funded by the authors and did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

#### **Conflict Of Interest**

No any conflict of interest was reported in thus study

# **References:-**

- 1. Glaser DL, Kaplan FS. Osteoporosis. Definition and clinical presentation. *Spine (Phila Pa 1976)*. 1997;22(24 Suppl):12S-16S. doi:10.1097/00007632-199712151-00003
- Sadat-Ali M, Al-Habdan IM, Al-Turki HA, Azam MQ. An epidemiological analysis of the incidence of osteoporosis and osteoporosis-related fractures among the Saudi Arabian population. *Ann Saudi Med*. 2012;32(6):637-641. doi:10.5144/0256-4947.2012.637
- 3. Svedbom A, Hernlund E, Ivergård M, et al. Osteoporosis in the European Union: a compendium of countryspecific reports. *Arch Osteoporos*. 2013;8(1-2):137. doi:10.1007/s11657-013-0137-0
- 4. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. *Cell*. 2006;125(2):247-260. doi:10.1016/j.cell.2006.01.051
- 5. Macdonald HM, New SA, Campbell MK, Reid DM. Influence of weight and weight change on bone loss in perimenopausal and early postmenopausal Scottish women. *Osteoporos Int a J Establ as result Coop between Eur Found Osteoporos Natl Osteoporos Found USA*. 2005;16(2):163-171. doi:10.1007/s00198-004-1657-7
- 6. Uusi-Rasi K, Sievänen H, Pasanen M, Oja P, Vuori I. Association of physical activity and calcium intake with the maintenance of bone mass in premenopausal women. *Osteoporos Int a J Establ as result Coop between Eur Found Osteoporos Natl Osteoporos Found USA*. 2002;13(3):211-217. doi:10.1007/s001980200016
- 7. Khan A. Premenopausal women and low bone density. *Can Fam Physician*. 2006;52(6):743-747. https://pubmed.ncbi.nlm.nih.gov/16812966
- 8. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis. *Thyroid*. 2003;13(6):585-593. doi:10.1089/105072503322238854
- 9. Williams GR, Bassett JHD. Thyroid diseases and bone health. *J Endocrinol Invest*. 2018;41(1):99-109. doi:10.1007/s40618-017-0753-4
- 10. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. *J bone Miner Res Off J Am Soc Bone Miner Res.* 1989;4(3):283-291. doi:10.1002/jbmr.5650040302
- 11. Bezerra de Carvalho KS, Vasco RF V, Custodio MR, Jorgetti V, Moysés RMA, Elias RM. Chronic kidney disease is associated with low BMD at the hip but not at the spine. *Osteoporos Int a J Establ as result Coop between Eur Found Osteoporos Natl Osteoporos Found USA*. 2019;30(5):1015-1023. doi:10.1007/s00198-019-04864-4
- 12. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. *Gastroenterology*. 2003;124(3):795-841. doi:10.1053/gast.2003.50106
- 13. van Hogezand RA, Hamdy NAT. Skeletal morbidity in inflammatory bowel disease. *Scand J Gastroenterol Suppl*. 2006;(243):59-64. doi:10.1080/00365520600664276
- 14. Compston J. Osteoporosis in inflammatory bowel disease. Gut. 2003;52(1):63-64. doi:10.1136/gut.52.1.63
- 15. Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. *Am J Med.* 2009;122(7):599-604. doi:10.1016/j.amjmed.2009.01.022
- 16. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut.* 1997;40(2):228-233. doi:10.1136/gut.40.2.228
- 17. Kemppainen T, Kröger H, Janatuinen E, et al. Osteoporosis in adult patients with celiac disease. *Bone*. 1999;24(3):249-255. doi:10.1016/s8756-3282(98)00178-1
- 18. Bottaro G, Cataldo F, Rotolo N, Spina M, Corazza GR. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. *Am J Gastroenterol*. 1999;94(3):691-696. doi:10.1111/j.1572-0241.1999.00938.x
- 19. West J, Logan RFA, Card TR, Smith C, Hubbard R. Fracture risk in people with celiac disease: a population-based cohort study. *Gastroenterology*. 2003;125(2):429-436. doi:10.1016/s0016-5085(03)00891-6
- 20. Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. *J bone Miner Res Off J Am Soc Bone Miner Res.* 1999;14(4):652-657. doi:10.1359/jbmr.1999.14.4.652
- Al-Dalaan A, Bahabri S, Al Ballaa S, Al Sukait M, Biyari T, Mousa M. The prevalence of rheumatoid arthritis in the Qassim Region of Saudi Arabia. Ann Saudi Med. 1998;18(5):396-397. doi:10.5144/0256-4947.1998.396
- 22. Awad SAS, Ashraf EM, Khaled AS, et al. The epidemiology of thyroid diseases in the Arab world: A systematic review. *J Public Heal Epidemiol*. 2016;8(2):17-26. doi:10.5897/jphe2015.0713
- 23. Moradi-Lakeh M, El Bcheraoui C, Tuffaha M, et al. Tobacco consumption in the Kingdom of Saudi Arabia, 2013: findings from a national survey. *BMC Public Health*. 2015;15:611. doi:10.1186/s12889-015-1902-3

- 24. Seo GH, Kang HY, Choe EK. Osteoporosis and fracture after gastrectomy for stomach cancer: A nationwide claims study. *Medicine (Baltimore)*. 2018;97(17):e0532-e0532. doi:10.1097/MD.000000000010532
- 25. Al-Raddadi R, Bahijri S, Borai A, AlRaddadi Z. Prevalence of lifestyle practices that might affect bone health in relation to vitamin D status among female Saudi adolescents. *Nutrition*. 2018;45:108-113. doi:10.1016/j.nut.2017.07.015
- 26. Al-Daghri NM. Vitamin D in Saudi Arabia: Prevalence, distribution and disease associations. J Steroid Biochem Mol Biol. 2018;175:102—107. doi:10.1016/j.jsbmb.2016.12.017
- 27. Giustina A, Adler RA, Binkley N, et al. Controversies in Vitamin D: Summary Statement From an International Conference. *J Clin Endocrinol Metab*. 2019;104(2):234-240. doi:10.1210/jc.2018-01414
- 28. Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. *Best Pract Res Clin Endocrinol Metab.* 2011;25(4):585-591. doi:10.1016/j.beem.2011.05.002
- 29. Yetley EA. Assessing the vitamin D status of the US population. *Am J Clin Nutr.* 2008;88(2):558S-564S. doi:10.1093/ajcn/88.2.558S
- 30. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. *Am J Clin Nutr*. 2007;85(3):860-868. doi:10.1093/ajcn/85.3.860
- 31. Agrawal M, Arora S, Li J, et al. Bone, inflammation, and inflammatory bowel disease. *Curr Osteoporos Rep*. 2011;9(4):251-257. doi:10.1007/s11914-011-0077-9
- 32. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. *Endocrinology*. 1994;134(1):169-176. doi:10.1210/endo.134.1.8275930
- 33. Blum MR, Bauer DC, Collet T-H, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. *JAMA*. 2015;313(20):2055-2065. doi:10.1001/jama.2015.5161
- 34. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. *Bone*. 1997;21(1):93-99. doi:10.1016/s8756-3282(97)00078-1
- 35. Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2009;94(7):2306-2312. doi:10.1210/jc.2008-2006
- De Geronimo S, Romagnoli E, Diacinti D, D'Erasmo E, Minisola S. The risk of fractures in postmenopausal women with primary hyperparathyroidism. *Eur J Endocrinol.* 2006;155(3):415-420. doi:10.1530/eje.1.02225
- Alsuwaida A, Farag Y, Al Sayyari A, et al. Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) A pilot study YR 2010/12/1. Saudi J Kidney Dis Transplant. (6 UL-https://www.sjkdt.org/article.asp?issn=1319-2442;year=2010;volume=21;issue=6;spage=1066;epage=1072;aulast=Alsuwaida;t=5):1066 OP-1072 VO 21.
- 38. Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis.* 2007;66(12):1560-1567. doi:10.1136/ard.2007.072157
- 39. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. *J bone Miner Res Off J Am Soc Bone Miner Res.* 2000;15(6):993-1000. doi:10.1359/jbmr.2000.15.6.993
- 40. Cooney JK, Law R-J, Matschke V, et al. Benefits of exercise in rheumatoid arthritis. J Aging Res. 2011;2011:681640. doi:10.4061/2011/681640
- 41. Gudbjornsson B, Juliusson UI, Gudjonsson F V. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. *Ann Rheum Dis.* 2002;61(1):32-36. doi:10.1136/ard.61.1.32
- 42. Al-Bashaireh AM, Haddad LG, Weaver M, Chengguo X, Kelly DL, Yoon S. The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms. *J Osteoporos*. 2018;2018:1206235. doi:10.1155/2018/1206235
- 43. Alotaibi SA, Durgampudi PK. Factors associated with tobacco smoking among Saudi college students: A systematic review. *Tob Prev Cessat.* 2020;6:36. doi:10.18332/tpc/122444
- 44. Drake MT. Osteoporosis and cancer. *Curr Osteoporos Rep.* 2013;11(3):163-170. doi:10.1007/s11914-013-0154-3
- 45. Bazarbashi S, Al Eid H, Minguet J. Cancer Incidence in Saudi Arabia: 2012 Data from the Saudi Cancer Registry. *Asian Pac J Cancer Prev.* 2017;18(9):2437-2444. doi:10.22034/APJCP.2017.18.9.2437
- 46. Al-Hazzaa HM, Abahussain NA, Al-Sobayel HI, Qahwaji DM, Musaiger AO. Lifestyle factors associated with overweight and obesity among Saudi adolescents. *BMC Public Health.* 2012;12(1):354.

doi:10.1186/1471-2458-12-354

- 47. Al-Hazzaa HM, Abahussain NA, Al-Sobayel HI, Qahwaji DM, Alsulaiman NA, Musaiger AO. Prevalence of overweight, obesity, and abdominal obesity among urban Saudi adolescents: gender and regional variations. *J Health Popul Nutr*. 2014;32(4):634-645. https://pubmed.ncbi.nlm.nih.gov/25895197
- 48. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. *Curr Opin Rheumatol*. 2018;30(2):144—150. doi:10.1097/bor.00000000000480
- 49. Bultink IEM. Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus. *Calcif Tissue Int.* 2018;102(5):575-591. doi:10.1007/s00223-017-0322-z